Centella asiatica extract
Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 84696-21-9
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
TNF-α |
IL-6 |
IL-5 |
IL-17 |
Centella asiatica extract (100-500 µg/mL; 1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α) dose-dependently reduces the expression levels of pro-inflammatory proteins COX-2 and IL-6 in IFN-γ/TNF-α-stimulated human keratinocyte HaCaT cells[3].
Centella asiatica extract (200 μg/mL; pre-incubated for 30 min prior to 24 h LPS stimulation) alters the mRNA expression of Il10 in RAW264.7 mouse macrophages stimulated with low glucose and LPS (HY-D1056)[4].
Centella asiatica extract (200 μg/mL; 30 min pre-incubation prior to 24 h LPS stimulation) inhibits the polarization of high glucose plus LPS-stimulated RAW264.7 mouse macrophages toward pro-inflammatory M1 macrophages by reducing the mRNA expression of Ccl2, Il6, Il1b and Tnf[4].
Centella asiatica extract (CA) (10-1000 µg/mL; 24 h) shows no cytotoxicity against HaCaT human keratinocytes at concentrations up to 500 µg/mL, while cytotoxicity is observed starting from the concentration of 600 µg/mL[3].
Centella asiatica extract (100-500 µg/mL) has detectable polyphenol and flavonoid contents, and exhibits concentration-dependent ABTS and DPPH free radical scavenging activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT human keratinocytes
-
Concentration:10, 40, 70, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 µg/mL
-
Incubation Time:24 h
-
Result:Showed no cytotoxicity in HaCaT cells at concentrations ranging from 10 µg/mL to 500 µg/mL, with cell viability remaining above 100% relative to the control.
Reduced cell viability to 48.46% at 600 µg/mL CA.
-
Cell Line:IFN-γ/TNF-α-stimulated HaCaT human keratinocytes
-
Concentration:100, 300, 500 µg/mL
-
Incubation Time:1 h pre-incubation; 24 h stimulation with IFN-γ/TNF-α
-
Result:Reduced COX-2 expression to 0.9-fold, 0.6-fold, and 0.4-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
Reduced IL-6 expression to 0.9-fold, 0.4-fold, and 0.3-fold relative to the stimulated control at 100 µg/mL, 300 µg/mL, and 500 µg/mL CA, respectively.
-
Cell Line:RAW264.7 mouse macrophage cell line (high glucose condition)
-
Concentration:200 μg/mL
-
Incubation Time:30 min pre-incubation prior to 24 h LPS stimulation
-
Result:Alleviated mRNA relative expression levels of the M1 pro-inflammatory markers Ccl2, Il6, Il1b, and Tnf.
Had no effect on Il10 and Mgl1 mRNA expression levels.
Showed inconsistent elevation of Cd206 mRNA expression under high glucose+LPS conditions.
Centella asiatica extract (80 µg/cm2; topical skin administration; once daily; 14 days; 200 mg/kg; oral administration; once daily; 14 days) alleviates DNCB-induced atopic dermatitis symptoms in BALB/c mice, including ear swelling, lymph node enlargement, skin hyperplasia, mast cell infiltration, and the expression of pro-inflammatory cytokines and signaling proteins[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Danio rerio (larvae, 0-2 hours post-fertilization to 9 days post-fertilization, hypoxic-ischemic injury model)[2]
-
Dosage:1.25 μg/mL; 2.5 μg/mL; 5 μg/mL
-
Administration:continuous; 6 days
-
Result:Increased average BDNF expression to 36.2 at 3 days post-fertilization and 35.92 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 34.82 at 3 days post-fertilization and 36.26 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Increased average BDNF expression to 36.19 at 3 days post-fertilization and decreased it to 34.09 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 34.66 and 35.33 respectively.
Decreased average VGLUT1 expression to 27.54 at 3 days post-fertilization and increased it to 32.95 at 9 days post-fertilization with 1.25 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 32.65 at 3 days post-fertilization and decreased it to 31.19 at 9 days post-fertilization with 2.5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
Increased average VGLUT1 expression to 33.45 at 3 days post-fertilization and decreased it to 32.08 at 9 days post-fertilization with 5 μg/mL, compared to hypoxic control's 32.64 and 32.23 respectively.
-
Animal Model:BALB/c (8-week-old female, DNCB-induced atopic dermatitis)[3]
-
Dosage:80 µg/cm2 (skin local); 200 mg/kg (p.o.)
-
Administration:skin local; daily; 14 days; p.o.; daily; 14 days
-
Result:Reduced ear thickness 1.3-fold (80 µg/cm2 skin local) and 1.2-fold (200 mg/kg oral) relative to untreated DNCB-induced mice.
Reduced lymph node weight 1.6-fold in both treatment groups compared to untreated DNCB-induced mice.
Reduced epidermal thickness 2.7-fold (skin local) and 1.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced dermal thickness 10.1-fold (skin local) and 5.9-fold (oral) relative to untreated DNCB-induced mice.
Reduced mast cell infiltration 4.4-fold (skin local) and 3.7-fold (oral) compared to untreated DNCB-induced mice.
Reduced mRNA expression of TNF-α 5.6-fold (skin local) and 12.9-fold (oral), IL-5 5.6-fold (skin local) and 11.5-fold (oral), IL-10 3.2-fold (skin local) and 9.5-fold (oral), IL-6 12.6-fold (skin local) and 1.7-fold (oral), as well as iNOS, COX-2, and CXCL9 relative to untreated DNCB-induced mice.
Reduced protein expression of TNF-α 2.7-fold (skin local) and 1.6-fold (oral), COX-2 2.9-fold (skin local) and 1.7-fold (oral), MAC-1 1.5-fold (skin local) and 1.6-fold (oral), and IL-6 3.4-fold in both groups relative to untreated DNCB-induced mice.
Suppressed p-p38 protein expression 1.4-fold (skin local) and 1.7-fold (oral) relative to untreated DNCB-induced mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 84696-21-9
-
SMILES
[Centella asiatica extract]
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Centella asiatica extract Related Classifications
HY-N18667 Related Classifications
Powered by Bioz